Minerva Imaging

Minerva Imaging is a science-driven Contract Research Organisation (CRO) and Contract Development and Manufacturing Organisation (CDMO) specialising in targeted radioligand therapies — a transformative, fast-emerging field in cancer therapeutics. With deep expertise in molecular imaging and advanced oncology and cardiovascular disease models, Minerva delivers a fully integrated platform that combines scientific excellence with end-to-end service capabilities.

Company Background

• Founded in 2011, Minerva has rapidly established itself as a frontrunner in the radiopharmaceuticals sector.
• Headquartered in Denmark, the company employs more than 150 highly skilled professionals, including a large number of PhD-level scientists.
• Delivers an integrated service model across the full pre-clinical and clinical development process.
• Collaborates with many of the world’s leading pharmaceutical and biotechnology companies and is widely recognised for its cutting-edge expertise in molecular imaging and advanced disease models.

Vision & Outlook

• Build a global market-leading radiopharmaceutical platform.
• Expand internationally, broadening Minerva Imaging’s integrated CRO and CDMO service offering to meet the needs of a growing global customer base.
• Leverage Nordic Capital’s subsector expertise, broad network, and track record in scaling healthcare businesses to support Minerva Imaging’s international expansion and accelerate the company’s mission of transforming translational research and drug development in oncology and cardiovascular disease.